Trending...
- New Book Warring From the Standpoint of the Throne Room Calls Believers to Pray From Victory
- Scotch Whisky Market Dislocation Creates Compelling Entry Opportunity for Long-Term Investors
- $317M Revenue and a Clear Path to $1B: $IQST is Positioned for a Major Profitability Inflection
Proposed five-year agreement positions Covalent Medical to commercialize ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye portfolio across physician-dispensed and national retail channels, with launch targeted for Q1 2027
DALLAS - nvtip -- ClearSight Therapeutics Signs Letter of Intent with Covalent Medical to Expand OTC Eye Care Portfolio Through Multi-Channel Commercial Partnership
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on nvtip.com
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on nvtip.com
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
DALLAS, TX — [February 24, 2026] — ClearSight Therapeutics, Inc., an innovator in over-the-counter ophthalmic solutions, today announced the signing of a non-binding Letter of Intent (LOI) with Covalent Medical, LLC to establish a private-label manufacturing and supply partnership for ClearSight's OTC Artificial Tears+, Contact Lens Rewetting Drops, and Pink Eye Products.
Under the proposed partnership, Covalent Medical intends to commercialize ClearSight's portfolio through both physician-dispensed and retail channels. The products will be introduced under Covalent's existing professional brand, Focus Tears, distributed directly through eye care practices nationwide, as well as under a new retail-focused brand targeting major national retailers.
Illustrative projections included in the LOI outline a potential five-year commercial relationship valued at approximately $60 million, reflecting anticipated product volumes across both clinical and retail markets.
The parties are currently negotiating definitive terms, with initial commercial launch anticipated in Q1 2027.
More on nvtip.com
- 106 Years Strong: The Liberty Group Celebrates a Century-Plus of Service and Unveils a Unified Family of Companies
- Airport Transportation Reaches All Five Continents Through Global Transportation Partner Network
- Vegas Ailure Launches Agent Ailure, an Agentic AI Travel Architect for the Las Vegas Strip
- Acquisition of Israeli Defense Manufacturing Platform to Accelerate AI-Driven Autonomous Systems: VisionWave Holdings, Inc.: (N A S D A Q: VWAV)
- HRC Fertility to Celebrate Grand Opening of New Beverly Hills Location During National Infertility Awareness Week
"This agreement represents a significant milestone for ClearSight and validates both our product portfolio and manufacturing platform," said Patrick Smale, CEO of ClearSight Therapeutics. "Covalent's leadership, commercial infrastructure, and deep relationships across eye care providers and retail partners position them to accelerate market adoption of our OTC ophthalmic solutions."
Clint Worley, COO of Covalent Medical, added, "ClearSight's portfolio aligns closely with our strategy to expand across both professional and consumer channels. Their manufacturing expertise and regulatory foundation provide an ideal platform for building differentiated eye care brands."
Bob Zatarain, Head of Sales and Business Development and Board Member at Covalent Medical, commented, "Having spent over two decades in the ophthalmic industry, I recognize the importance of delivering accessible, high-quality OTC solutions. This partnership strengthens Covalent's ability to serve both practitioners and patients with innovative, compliant products."
Dr. Kairy Barazi, Founder and CEO of Covalent Medical, added, "Our focus has always been on identifying clinically grounded solutions that meet real patient needs. ClearSight's approach to product development and quality aligns well with our long-term vision for expanding access to modern eye care."
Under the proposed structure, ClearSight will retain responsibility for manufacturing, quality assurance, and regulatory compliance, while Covalent will oversee branding, packaging, and commercialization across designated channels.
More on nvtip.com
- AktieGo Publishes Editorial Feature Examining Decentralized Power Infrastructure and Hydrogen Energy Deployment
- OWNER/CEO: Edward Rawlinson of Southside Recordz ~ (THE CONGLOMERATE) files "Civil Lawsuit"
- Greg Wier Announces the Release of More Than Just Luck
- Nieuwe standaard in webdesign: Professionele website laten maken voor het MKB vanaf €249 door Websitepioniers
- Shipping Containers Are Powering the Next Generation of Bitcoin Mining Infrastructure
The companies intend to finalize a definitive agreement later this year, with commercialization targeted for 2027.
About ClearSight Therapeutics
Clearsight Therapeutics was founded by a team of eye care industry veterans and partners to develop better solutions to common eye conditions such as dry eye and pink eye, which continue to disrupt the lives of millions of patients. Clearsight is committed to ethical and responsible biotech research and development. With a patient-first approach, the company is dedicated to making OTC eye care products that are safe, effective, and accessible to all. For more information visit www.clearsighttx.com.
About Covalent Medical
Covalent Medical, LLC was formed by over 400 retina specialists in 2011 and is one of the largest commercial organization of retina specialists in the country. Covalent Medical, which owns the brands name Focus Vitamins and SightGuardian, is a patient-focused company that produces research-based eye vitamins and OTC products with a focus on quality and safety, and are sold directly through eyecare professionals, on-line retailers, and on their website. For more information, visit www.focusvitamins.com.
# # #
Media Contact(s):
ClearSight - Patrick Smale, CEO
972-983-7761
patrick@clearsighttx.com
Covalent Medical – Clint Worley, COO
703-832-5869
cworley@focusvitamins.com
Source: ClearSight Therapeutics, Inc.
Filed Under: Health
0 Comments
Latest on nvtip.com
- $6 Million Funding Secured as Retail Expansion, Operational Streamlining, and Asset-Light Strategy Position the Company for Accelerated Growth $SOWG
- The "Unsexy" Business Quietly Creating 130+ New Entrepreneurs Across America — From Alaska to Puerto Rico
- Veteran Launches GTG Energy: Nicotine-Free Pouch as Americans Rethink Addiction, Focus, and What Fuels Performance
- Las Vegas Realtor Trang Hooser Launches Full-Price Cash Offer Service to Eliminate Home Selling Stress
- RecallSentry™ App Launch — Your Home Safety Hub — Free on iOS & Android
- Award-Winning Director Crystal J. Huang's Under-$50K Film "The Ritual House" Wins Best Horror Feature at Golden State Film Festival
- Grads aren't getting hired — here's what we're doing about it
- K2 Integrity Enhances Technology Capabilities Through Acquisition of Leviathan Security Group
- #WeAreGreekWarriors Comes to Detroit in Celebration of Women's History Month
- Buildout Launches CRM, Completing the Industry's First AI-Powered End-to-End Deal Engine for CRE
- Energywise Solutions and Pickleball Pros Partner to Bring More Energy and Visibility to Pickleball Clubs
- Crovetti Orthopaedics Launches URKnee™ - Aligning Patient-Defined Outcomes and Rehabilitation Strategy for Knee Replacement
- The Franchise King® Releases Free Guide for Nervous Buyers
- Kanguro Insurance Taps Paylode to Launch Best-in-Class Pet and Renters Insurance Rewards Experience
- CCHR: CIA Mind-Control Files Raise Urgent Questions as Millions Take Psychotropic Drugs
- NRx Pharmaceuticals Launches Breakthrough One-Day Treatment Clinic in Florida as FDA Pathway and Clinical Data Strengthen Growth Outlook; $NRXP
- Revenue Optics Launches Talent Infrastructure Platform for SaaS Revenue Hiring and Appoints Sabz Kaur to Lead Growth
- Building a Multi-Domain Autonomous Systems Platform at the Intersection of AI, Defense and Infrastructure: VisionWave Holdings (N A S D A Q: VWAV)
- Bent Danholm Named "Top Luxury Real Estate Leader" in Modern Luxury Miami
- Author Ken Mora to Celebrate New Caravaggio Book Debut with Special Event at Palazzo Venezia Naples